Unveiling Shared and Disease-Specific Metabolic Disruptions in Three Chronic Cardiovascular Diseases

Multimorbidity, defined as the coexistence of multiple chronic conditions, is a growing global health challenge. Understanding the metabolic relationships among these conditions, as well as identifying specific metabolites that can differentiate between them, will offer valuable biological insights into their co-occurrence. We employed untargeted plasma metabolomics and machine learning to analyze metabolic changes and associations linked to three chronic cardiovascular diseases—deep venous thrombosis (DVT), hypertension (HPT) and coronary heart disease (CHD)—in a cohort of 196 subjects. Our analysis revealed that 134 metabolites that were common to at least two of these diseases, representing 54.3% of the total 409 significant metabolite-disease associations. The results shows that lipids, amino acids and peptides, hypoxanthine, carnitines and Glucose exhibited interconnected roles across multiple chronic cardiovascular diseases. Additionally, numerous carnitines were found to be specifically linked to DVT and CHD, while the DVT displayed pronounced disruptions in amino acid metabolism. By employing logistic regression models, we identified differential metabolites associated with the three chronic cardiovascular diseases, which demonstrated strong diagnostic performance in both the discovery and validation cohorts. Altogether, our study uncovered extensive and interconnected metabolic dysregulation across the three chronic cardiovascular diseases. The identified differential metabolites hold potential for diagnosing these conditions and offer valuable insights for future clinical interventions and management strategies grounded in metabolomics approaches.

Multimorbidity; metabolomics; metabolites; chronic cardiovascular disease; associations; deep venous thrombosis

1. Al-Akwaa, F. M., Yunits, B., Huang, S., Alhajaji, H., & Garmire, L. X. (2018, Dec 1). Lilikoi: an R package for personalized pathway-based classification modeling using metabolomics data. Gigascience, 7(12). https://doi.org/10.1093/gigascience/giy136 [Google Scholar] [Crossref]

2. Al Ashmar, S., Anwardeen, N. R., Anlar, G. G., Pedersen, S., Elrayess, M. A., & Zeidan, A. (2024). Metabolomic profiling reveals key metabolites associated with hypertension progression. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1284114 [Google Scholar] [Crossref]

3. Ameta, K., Gupta, A., Kumar, S., Sethi, R., Kumar, D., & Mahdi, A. A. (2017, May 19). Essential hypertension: A filtered serum based metabolomics study. Scientific Reports, 7(1), 2153. https://doi.org/10.1038/s41598-017-02289-9 [Google Scholar] [Crossref]

4. Caillon, A., & Schiffrin, E. L. (2016, Mar). Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence. Current Hypertension Reports, 18(3), 21. https://doi.org/10.1007/s11906-016-0628-7 [Google Scholar] [Crossref]

5. Colin A. Smith, E. J. W., Grace O’Maille, Ruben Abagyan, and Gary Siuzdak. (2006). XCMS: Processing Mass Spectrometry Data For Metabolite Profiling-Using Nonlinear Peak Alignment. Analytical Chemistry, 78, 779-787. [Google Scholar] [Crossref]

6. Franczyk, B., Gluba-Brzozka, A., Lawinski, J., Rysz-Gorzynska, M., & Rysz, J. (2021, Jul 29). Metabolomic Profile in Venous Thromboembolism (VTE). Metabolites, 11(8). https://doi.org/10.3390/metabo11080495 [Google Scholar] [Crossref]

7. Fromentin, S., Forslund, S. K., Chechi, K., Aron-Wisnewsky, J., Chakaroun, R., Nielsen, T., Tremaroli, V., Ji, B., Prifti, E., Myridakis, A., Chilloux, J., Andrikopoulos, P., Fan, Y., Olanipekun, M. T., Alves, R., Adiouch, S., Bar, N., Talmor-Barkan, Y., Belda, E., Caesar, R., Coelho, L. P., Falony, G., Fellahi, S., Galan, P., Galleron, N., Helft, G., Hoyles, L., Isnard, R., Le Chatelier, E., Julienne, H., Olsson, L., Pedersen, H. K., Pons, N., Quinquis, B., Rouault, C., Roume, H., Salem, J. E., Schmidt, T. S. B., Vieira-Silva, S., Li, P., Zimmermann-Kogadeeva, M., Lewinter, C., Sondertoft, N. B., Hansen, T. H., Gauguier, D., Gotze, J. P., Kober, L., Kornowski, R., Vestergaard, H., Hansen, T., Zucker, J. D., Hercberg, S., Letunic, I., Backhed, F., Oppert, J. M., Nielsen, J., Raes, J., Bork, P., Stumvoll, M., Segal, E., Clement, K., Dumas, M. E., Ehrlich, S. D., & Pedersen, O. (2022, Feb). Microbiome and metabolome features of the cardiometabolic disease spectrum. Nature Medicine, 28(2), 303-314. https://doi.org/10.1038/s41591-022-01688-4 [Google Scholar] [Crossref]

8. Gao, H., & Liu, S. (2017, Sep 15). Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sciences, 185, 23-29. https://doi.org/10.1016/j.lfs.2017.07.027 [Google Scholar] [Crossref]

9. Gong, Y., Ji, P., Yang, Y. S., Xie, S., Yu, T. J., Xiao, Y., Jin, M. L., Ma, D., Guo, L. W., Pei, Y. C., Chai, W. J., Li, D. Q., Bai, F., Bertucci, F., Hu, X., Jiang, Y. Z., & Shao, Z. M. (2021, Jan 5). Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metabolism, 33(1), 51-64 e59. https://doi.org/10.1016/j.cmet.2020.10.012 [Google Scholar] [Crossref]

10. Jaagura, M., Kronberg, J., Reigo, A., Aasmets, O., Nikopensius, T., Vosa, U., Bomba, L., Estonian Biobank research, t., Estrada, K., Wuster, A., Esko, T., & Org, E. (2024, Oct 22). Comorbidities confound metabolomics studies of human disease. Scientific Reports, 14(1), 24810. https://doi.org/10.1038/s41598-024-75556-1 [Google Scholar] [Crossref]

11. Jiang, W., Yang, L., Dang, Y., Jiang, X., Wu, L., Tong, X., Guo, J., & Bao, Y. (2024, Apr). Metabolomic profiling of deep vein thrombosis. Phlebology, 39(3), 154-168. https://doi.org/10.1177/02683555231215199 [Google Scholar] [Crossref]

12. Jiang, X., Zeleznik, O. A., Lindstrom, S., Lasky-Su, J., Hagan, K., Clish, C. B., Eliassen, A. H., Kraft, P., & Kabrhel, C. (2018, Nov 20). Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis. Journal of the American Heart Association, 7(22), e010317. https://doi.org/10.1161/JAHA.118.010317 [Google Scholar] [Crossref]

13. Jurisson, M., Pisarev, H., Uuskula, A., Lang, K., Oona, M., & Kalda, R. (2021, Oct 5). Prevalence of chronic conditions and multimorbidity in Estonia: a population-based cross-sectional study. BMJ Open, 11(10), e049045. https://doi.org/10.1136/bmjopen-2021-049045 [Google Scholar] [Crossref]

14. Karczewski, K. J., & Snyder, M. P. (2018, May). Integrative omics for health and disease. Nat Rev Genet, 19(5), 299-310. https://doi.org/10.1038/nrg.2018.4 [Google Scholar] [Crossref]

15. Ke, C., Zhu, X., Zhang, Y., & Shen, Y. (2018). Metabolomic characterization of hypertension and dyslipidemia. Metabolomics, 14(9). https://doi.org/10.1007/s11306-018-1408-y [Google Scholar] [Crossref]

16. Ku, G., Thomas, C. E., Akeson, A. L., & Jackson, R. L. (1992, Jul 15). Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. Journal of Biological Chemistry, 267(20), 14183-14188. [Google Scholar] [Crossref]

17. Lavi, S., McConnell, J. P., Rihal, C. S., Prasad, A., Mathew, V., Lerman, L. O., & Lerman, A. (2007, May 29). Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation, 115(21), 2715-2721. https://doi.org/10.1161/CIRCULATIONAHA.106.671420 [Google Scholar] [Crossref]

18. Liu, H., Zhang, H., Zhang, X., Chen, Q., & Xia, L. (2022). Role of succinic acid in the regulation of sepsis. International Immunopharmacology, 110. https://doi.org/10.1016/j.intimp.2022.109065 [Google Scholar] [Crossref]

19. Liu, Q., Li, B., Li, Y., Wei, Y., Huang, B., Liang, J., You, Z., Li, Y., Qian, Q., Wang, R., Zhang, J., Chen, R., Lyu, Z., Chen, Y., Shi, M., Xiao, X., Wang, Q., Miao, Q., Fang, J. Y., Gershwin, M. E., Lian, M., Ma, X., & Tang, R. (2022, May). Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut, 71(5), 899-909. https://doi.org/10.1136/gutjnl-2020-323565 [Google Scholar] [Crossref]

20. Liu, W., Guo, P., Dai, T., Shi, X., Shen, G., & Feng, J. (2021, May 7). Metabolic Interactions and Differences between Coronary Heart Disease and Diabetes Mellitus: A Pilot Study on Biomarker Determination and Pathogenesis. Journal of Proteome Research, 20(5), 2364-2373. https://doi.org/10.1021/acs.jproteome.0c00879 [Google Scholar] [Crossref]

21. Makide, K., Kitamura, H., Sato, Y., Okutani, M., & Aoki, J. (2009, Sep). Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins and Other Lipid Mediators, 89(3-4), 135-139. https://doi.org/10.1016/j.prostaglandins.2009.04.009 [Google Scholar] [Crossref]

22. Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T. T. J., Havulinna, A. S., Lindbohm, J. V., Ahola-Olli, A., Kurki, M., Karjalainen, J., Palta, P., FinnGen, Neale, B. M., Daly, M., Salomaa, V., Palotie, A., Widen, E., & Ripatti, S. (2020, Apr). Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nature Medicine, 26(4), 549-557. https://doi.org/10.1038/s41591-020-0800-0 [Google Scholar] [Crossref]

23. Myers, D., Lester, P., Adili, R., Hawley, A., Durham, L., Dunivant, V., Reynolds, G., Crego, K., Zimmerman, Z., Sood, S., Sigler, R., Fogler, W., Magnani, J., Holinstat, M., & Wakefield, T. (2020 ). A New Way to Treat Proximal Deep Venous Thrombosis using E-Selectin Inhibition. J Vasc Surg Venous Lymphat Disord., 8(2), 268–278. https://doi.org/10.1016/j.jvsv.2019.08.016 [Google Scholar] [Crossref]

24. Nayeem, M. A. (2018, Jul). Role of oxylipins in cardiovascular diseases. Acta Pharmacologica Sinica, 39(7), 1142-1154. https://doi.org/10.1038/aps.2018.24 [Google Scholar] [Crossref]

25. Nieman, D. C., Shanely, R. A., Luo, B., Meaney, M. P., Dew, D. A., & Pappan, K. L. (2014, Jul 1). Metabolomics approach to assessing plasma 13- and 9-hydroxy-octadecadienoic acid and linoleic acid metabolite responses to 75-km cycling. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 307(1), R68-74. https://doi.org/10.1152/ajpregu.00092.2014 [Google Scholar] [Crossref]

26. Omar, A. A., Nagah, M. A., Nesreen, A. M., Tariq, M. A. A., Yasir, W. A., Munif, S. A., Abdurhman, A. A., Amjad, H. A., Abdullah, H. A., & Ahmed, S. A. (2017). Deep Venous Thrombosis among hypertensive patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia. Electronic Physician, 9(10), 5472-5477. https://doi.org/10.19082/5472 [Google Scholar] [Crossref]

27. Palmu, J., Tikkanen, E., Havulinna, A. S., Vartiainen, E., Lundqvist, A., Ruuskanen, M. O., Perola, M., Ala-Korpela, M., Jousilahti, P., Wurtz, P., Salomaa, V., Lahti, L., & Niiranen, T. (2022, Mar 1). Comprehensive biomarker profiling of hypertension in 36 985 Finnish individuals. Journal of Hypertension, 40(3), 579-587. https://doi.org/10.1097/HJH.0000000000003051 [Google Scholar] [Crossref]

28. Pietzner, M., Stewart, I. D., Raffler, J., Khaw, K. T., Michelotti, G. A., Kastenmuller, G., Wareham, N. J., & Langenberg, C. (2021, Mar). Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nature Medicine, 27(3), 471-479. https://doi.org/10.1038/s41591-021-01266-0 [Google Scholar] [Crossref]

29. Polonis, K., Wawrzyniak, R., Daghir-Wojtkowiak, E., Szyndler, A., Chrostowska, M., Melander, O., Hoffmann, M., Kordalewska, M., Raczak-Gutknecht, J., Bartosinska, E., Kaliszan, R., Narkiewicz, K., & Markuszewski, M. J. (2020). Metabolomic Signature of Early Vascular Aging (EVA) in Hypertension. Frontiers in Molecular Biosciences, 7, 12. https://doi.org/10.3389/fmolb.2020.00012 [Google Scholar] [Crossref]

30. Sun, G. Y., Shelat, P. B., Jensen, M. B., He, Y., Sun, A. Y., & Simonyi, A. (2010, Jun). Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Medicine, 12(2), 133-148. https://doi.org/10.1007/s12017-009-8092-z [Google Scholar] [Crossref]

31. Sung, Y., Spagou, K., Kafeza, M., Kyriakides, M., Dharmarajah, B., Shalhoub, J., Diaz, J. A., Wakefield, T. W., Holmes, E., & Davies, A. H. (2018, May). Deep Vein Thrombosis Exhibits Characteristic Serum and Vein Wall Metabolic Phenotypes in the Inferior Vena Cava Ligation Mouse Model. European Journal of Vascular and Endovascular Surgery, 55(5), 703-713. https://doi.org/10.1016/j.ejvs.2018.01.027 [Google Scholar] [Crossref]

32. Terkeltaub, R., Banka, C. L., Solan, J., Santoro, D., Brand, K., & Curtiss, L. K. (1994, Jan). Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arteriosclerosis and Thrombosis, 14(1), 47-53. https://doi.org/10.1161/01.atv.14.1.47 [Google Scholar] [Crossref]

33. Teruya, T., Sunagawa, S., Mori, A., Masuzaki, H., & Yanagida, M. (2023, Feb 11). Markers for obese and non-obese Type 2 diabetes identified using whole blood metabolomics. Scientific Reports, 13(1), 2460. https://doi.org/10.1038/s41598-023-29619-4 [Google Scholar] [Crossref]

34. Touyz, R. M., Alves-Lopes, R., Rios, F. J., Camargo, L. L., Anagnostopoulou, A., Arner, A., & Montezano, A. C. (2018, Mar 15). Vascular smooth muscle contraction in hypertension. Cardiovascular Research, 114(4), 529-539. https://doi.org/10.1093/cvr/cvy023 [Google Scholar] [Crossref]

35. Trauelsen, M., Hiron, T. K., Lin, D., Petersen, J. E., Breton, B., Husted, A. S., Hjorth, S. A., Inoue, A., Frimurer, T. M., Bouvier, M., O'Callaghan, C. A., & Schwartz, T. W. (2021, Jun 15). Extracellular succinate hyperpolarizes M2 macrophages through SUCNR1/GPR91-mediated Gq signaling. Cell Reports, 35(11), 109246. https://doi.org/10.1016/j.celrep.2021.109246 [Google Scholar] [Crossref]

36. Wang, D., Strandgaard, S., Iversen, J., & Wilcox, C. S. (2009, Feb). Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 296(2), R195-200. https://doi.org/10.1152/ajpregu.90506.2008 [Google Scholar] [Crossref]

37. Xia Shen, C. W., Ningning Liang, Zhen Liu, Xinde Li, Zheng-Jiang Zhu, Tony R. Merriman, Nicola Dalbeth, Robert Terkeltaub, Changgui Li, and Huiyong Yin. (2021). Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout. Arthritis & Rheumatology, 73(9), 1738–1748. https://doi.org/10.1002/art.41733 [Google Scholar] [Crossref]

38. Xiao, Y., Ma, D., Yang, Y. S., Yang, F., Ding, J. H., Gong, Y., Jiang, L., Ge, L. P., Wu, S. Y., Yu, Q., Zhang, Q., Bertucci, F., Sun, Q., Hu, X., Li, D. Q., Shao, Z. M., & Jiang, Y. Z. (2022, May). Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Research, 32(5), 477-490. https://doi.org/10.1038/s41422-022-00614-0 [Google Scholar] [Crossref]

39. Xu, Y., Jiang, H., Li, L., Chen, F., Liu, Y., Zhou, M., Wang, J., Jiang, J., Li, X., Fan, X., Zhang, L., Zhang, J., Qiu, J., Wu, Y., Fang, C., Sun, H., & Liu, J. (2020). Branched-Chain Amino Acid Catabolism Promotes Thrombosis Risk by Enhancing Tropomodulin-3 Propionylation in Platelets. Circulation, 142(1), 49-64. https://doi.org/10.1161/circulationaha.119.043581 [Google Scholar] [Crossref]

40. Yang, W., & Zheng, Y. (2019). Causes of deep venous thrombosis after fracture in patients with coronary heart disease and intervention efficiency of argatroban. Journal of Clinical Medicine in Practice 20(045) https://doi.org/DOI: 10.7619/jcmp.201920013 [Google Scholar] [Crossref]

41. Zhang, K., Wang, P., Huang, W., Tang, S.-H., Xue, H., Wu, H., Zhang, Y., Rong, Y., Dong, S.-S., Chen, J.-B., Zou, Y., Tian, D., Yang, N., Liang, Y., Liu, C., Li, D., Zhang, K., Yang, T.-L., & Guo, Y. (2024). Integrated landscape of plasma metabolism and proteome of patients with post-traumatic deep vein thrombosis. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-52262-0 [Google Scholar] [Crossref]

42. Zhang, L., Zhang, Y., Ma, Z., Zhu, Y., & Chen, Z. (2021, Nov 30). Altered amino acid metabolism between coronary heart disease patients with and without type 2 diabetes by quantitative (1)H NMR based metabolomics. Journal of Pharmaceutical and Biomedical Analysis, 206, 114381. https://doi.org/10.1016/j.jpba.2021.114381 [Google Scholar] [Crossref]

43. Zhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y. X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., & Yu, J. (2021, Apr). Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut, 70(4), 761-774. https://doi.org/10.1136/gutjnl-2019-319664 [Google Scholar] [Crossref]

44. Zhang, Y., Zhao, H., Zhao, J., Lv, W., Jia, X., Lu, X., Zhao, X., & Xu, G. (2024, Aug 2). Quantified Metabolomics and Lipidomics Profiles Reveal Serum Metabolic Alterations and Distinguished Metabolites of Seven Chronic Metabolic Diseases. Journal of Proteome Research, 23(8), 3076-3087. https://doi.org/10.1021/acs.jproteome.3c00760 [Google Scholar] [Crossref]

• Measuring Waste of Patient Time in Health Care at Non-Digitized Hospital: An Observational Study in Bangabandhu Sheikh Mujib Medical University, Bangladesh
• Reaffirming Clinical Confidence in Atorvastatin Therapy: A Digital Outreach Case Study from Tamil Nadu, India
• Clinical Manifestations and Therapeutic Response in a Patient with Hypothyroidism: A Case Report
• Eranda (Ricinus Communis) In Gridhrasi (Sciatica): Classical Rationale, Pharmacology and Clinical Evidence- A Narrative Literature Review
• Magnetotherapy in Pain Management: Mechanisms, Clinical Applications, and Future Perspectives – A Review